– USA, MA – Paragonix Technologies, Inc. today announced the appointment of Dr. Lisa Anderson, Ph.D., to the role of CEO, succeeding William Edelman, who has served as Chairman and CEO since 2012 and announced his retirement. John Cammett, a Board member for over three years, will assume the role of Chairman of the Board of Directors.
“The depth and breadth of Dr. Anderson’s unique experience at Paragonix both from a clinical and well as multinational commercial development perspective underpins her natural progression into the role of CEO.” Mr. Cammett continued, “There is no better person to take over the helm of Paragonix than Lisa. The company has passed the proof of concept phase of commercialization and under Lisa’s leadership, the company will be establishing a new era of broad market adoption and expansion of technologies underpinning the product portfolio. Her leadership in the field of organ preservation and deep connection to the transplant community makes her the perfect leader for this new chapter in the company’s growth.” said new Board Chairman, John Cammett.
About Dr. Lisa Anderson
Dr. Lisa Anderson brings a wealth of experience to this role, having founded Paragonix and served as the COO for the past 10 years. Lisa has played a critical role in the continued growth, including commercially scaling the business across the United States and Europe, overseeing the launch of critically-acclaimed products, Paragonix SherpaPak Cardiac Transport System and the LUNGguard Donor Lung Preservation System, and the recent rollout of a first-of-its-kind digital platform for transplant team coordination and clinical logistics.
Dr. Anderson commented, “I am thrilled to lead a highly distinguished team that is on track to bring Paragonix to the next level by expanding our product profile and digitally integrating our full suite to empower both donation and transplant professionals. Our goal is to provide every transplant patient the advantage of advanced organ preservation through collaboration with all the varied stakeholders in the transplant community.” This next era for Paragonix is built upon the foundation Edelman cultivated: “Under Bill’s leadership, Paragonix defined the pathway to a new method of care, achieved multiple FDA clearances and CE marks, and launched two groundbreaking commercial products. We thank him for eleven years of dedicated service.”
About Paragonix Technologies
Paragonix Technologies designs, produces and markets organ preservation and transport devices that safeguard organs during the journey between donor and transplant recipient patients. Our award-winning devices mitigate risk in an otherwise high-stakes environment by combining best-in-class transplant products with a centralized communication and data transfer app to enable better coordination and efficiency during donor organ procurements. Paragonix SherpaPak CTS is the only commercially available FDA-cleared and CE-marked preservation and transport device for adult and pediatric donor hearts destined for transplantation. Paragonix is the sole sponsor of GUARDIAN, the largest international clinical data registry on heart preservation, capturing clinical outcome data on Paragonix SherpaPak CTS, and all other heart preservation technologies. Paragonix’s LUNGguard is the only FDA-cleared and CE-marked cold storage preservation and transport device for donor’s lungs and was commercially launched in the US and Europe in December 2020. Paragonix is also developing preservation devices for the pancreas, kidney, and liver — designed to improve donor organ quality and extend donor organ preservation time.
For more information: https://paragonixtechnologies.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.